Glaukos Corp · Health Care
$179.87
As of: 2026-08-30 04:47:47 (KST)
-43.9%
Expected return
25%
Success probability
-44.4%
Downside risk
For informational purposes only.
Not investment advice.
Glaukos Corp in the Health Care industry carries C grade, driven by a Monte Carlo rating of 13. With an expected return of -43.9% and a 25% chance of positive returns, the stock at $179.87 presents This assessment is based on 10,000 probabilistic scenarios, offering a robust view of the potential return distribution across varying market conditions.
The Reverse DCF analysis places this stock in the "Expensive" zone. The implied growth rate (g_implied) of 500.0%, compared with the actual growth rate of 15.0%, reveals the market's pricing assumptions. The P50 intrinsic value sits at $103, offering a reference point against the current price. At $185, the Reverse-DCF implied probability of finishing above $185 stands at 0%.
This C rating (13) suggests caution. The expected return of -43.9% and 25% success probability are below our threshold for an attractive entry.
The Monte Carlo distribution reveals a volatility of 0.6% — relatively low, meaning the simulated outcomes cluster tightly around the median. The P50 sits at -44.1%, with a +0.7% gap between P10 (-44.4%) and P75 (-43.7%). a negative skew suggests downside scenarios are more pronounced than upside ones
In the worst 5% of scenarios, the 5th percentile value-at-risk is -44.4%. On the operating side, the -31.6% operating margin provides a thin buffer against revenue declines. With a volatility of 0.6%, volatility risk is low at the current price of $180.
DCF estimates a company's intrinsic value by discounting its future cash flows to present value. Modelvix uses Monte Carlo simulation to analyze thousands of scenarios.
Learn more →WACC is the average rate a company pays to finance its assets, used as the discount rate in DCF analysis. Modelvix simulates how WACC changes affect valuation.
Learn more →Terminal value represents the perpetual value of a business beyond the forecast period, often comprising the majority of DCF value. Modelvix analyzes terminal value uncertainty across growth scenarios.
Learn more →Reverse DCF works backward from the current stock price to infer the growth rate the market expects, helping you assess whether a stock is fairly valued. Modelvix shows what growth assumptions the current price implies.
Learn more →